Pharma BD Deal Intelligence

Vertex Pharmaceuticals Incorporated / Exonics Therapeutics, Inc.

2019 · Acquisition/Merger · $1.0B · Complete

Vertex acquired Exonics Therapeutics for $245M upfront plus up to $755M in milestones (~$1B total). Concurrently expanded its collaboration with CRISPR Therapeutics on DMD/DM1 with a $175M upfront and $25M equity investment. Adds CRISPR gene editing platform for Duchenne and myotonic dystrophy.

Key facts

• Announced Jun 13, 2019
• Deal value $1.0B
• Deal type Acquisition/Merger
• Therapeutic area Duchenne muscular dystrophy, myotonic dystrophy type 1
• Indications Duchenne muscular dystrophy, myotonic dystrophy type 1
• Key assets SingleCut CRISPR gene editing platform
• Mechanism CRISPR/Cas9 gene editing

← Browse all deals  ·  How we score deals